X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SAGE-718 (dalzanemdor) is an oral, first-in-class investigational NMDA receptor positive allosteric modulator. It is being evaluated for the treatment of mild cognitive impairment in parkinson’s disease.
Lead Product(s): SAGE-718
Therapeutic Area: Neurology Product Name: SAGE-718
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
SAGE-718 is first-in-class NMDA receptor positive allosteric modulator and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including HD, PD and AD.
Lead Product(s): SAGE-718
Therapeutic Area: Genetic Disease Product Name: SAGE-718
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
Zurzuvae (zuranolone), a neuroactive steroid GABA-A receptor positive allosteric modulator, is the first and only oral, once-daily, 14-day treatment approved by FDA, that can provide rapid improvements in depressive symptoms for women with postpartum depression.
Lead Product(s): Zuranolone
Therapeutic Area: Psychiatry/Psychology Product Name: Zurzuvae
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2023
Details:
SAGE-217 (zuranolone) is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). Currently being developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Lead Product(s): Zuranolone
Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-217
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
SAGE-718 is first-in-class NMDA receptor positive allosteric modulator and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including HD, PD and AD.
Lead Product(s): SAGE-718
Therapeutic Area: Genetic Disease Product Name: SAGE-718
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
SAGE-217 (zuranolone) is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). Currently being developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Lead Product(s): Zuranolone
Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-217
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
SAGE-217 (zuranolone) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM).
Lead Product(s): Zuranolone
Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-217
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported.
Lead Product(s): Zuranolone
Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-217
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
Zuranolone (SAGE-217/BIIB125) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Lead Product(s): Zuranolone
Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-217
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
SAGE-217 (zuranolone), 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints.
Lead Product(s): Zuranolone
Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-217
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
